Navigation Links
Arigene Co., Ltd. Announces Termination of Tender Offer To Purchase and Return of Validly Tendered Shares of Common Stock of Trimeris, Inc.
Date:12/29/2009

SEOUL, South Korea, Dec. 29 /PRNewswire/ -- Arigene Co., Ltd., a Korean corporation traded on the Korean Securities Dealers Association Quotation System ("Arigene") (KOSDAQ: 067850), today announced the termination of the tender offer for the outstanding common stock of Trimeris, Inc. ("Trimeris") (Nasdaq: TRMS) by RTM Acquisition Company, a Delaware corporation and a wholly-owned subsidiary of Arigene ("RTM"), which was made pursuant to an Agreement and Plan of Merger dated as of October 2, 2009, and amended as of November 17, 2009, by and among Arigene, RTM and Trimeris, because Arigene was unable to secure sufficient financing for purposes of funding the tender offer and the merger as of the expiration time of the tender offer.

As of the expiration of the tender offer at 5:00 p.m., New York City time, on Monday, December 28, 2009, holders had tendered an aggregate of approximately 19,311,216 shares, or 86.4%, of Trimeris' common stock. None of the shares of Trimeris common stock validly tendered were purchased in the tender offer. Arigene has instructed the depositary for the tender offer to promptly return all shares of Trimeris common stock previously tendered and not withdrawn to their respective holders.

About Arigene Co., Ltd.

Arigene Co., Ltd. (KOSDAQ: 067850) is a developer, manufacturer and marketer of Ubiquitous Healthcare Systems (U-Healthcare) and related medical equipment in Korea. With its planned acquisition of Trimeris, Inc., Arigene is expanding its business to the broader biotechnology industry.

Additional Information

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Trimeris. Arigene has filed a tender offer statement on Schedule TO, as amended, with the SEC and has mailed an offer to purchase, forms of letter of transmittal and related documents to Trimeris stockholders. Trimeris has filed with the SEC and mailed to Trimeris stockholders, a solicitation/recommendation statement on Schedule 14D-9, as amended. These documents contain important information about the tender offer and the merger and stockholders of Trimeris are urged to read them carefully in their entirety, as well as any amendments or supplements to these documents, including the amendment to the Schedule TO filed with the SEC on December 29, 2009 regarding the termination of the tender offer. These materials were sent free of charge to all stockholders of Trimeris. Investors and security holders are also able to obtain free copies of the tender offer statement, the tender offer solicitation/recommendation statement and other documents filed with the SEC by Arigene and Trimeris through the web site maintained by the SEC at www.sec.gov.

SOURCE Arigene Co., Ltd.


'/>"/>
SOURCE Arigene Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Arigene Co., Ltd. Enters Into Amendment To Merger Agreement With Trimeris, Inc.
2. Vermillion Announces $43.05 Million Private Placement of Common Stock
3. ViVre Medical Announces $6,000,000 Gift
4. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
5. Maxygen, Inc. Announces Preliminary Results of Dutch Auction Tender Offer
6. Boston Scientific Announces Settlement of DOJ Investigation Relating to Post-Market Surveys Conducted By Guidant
7. Raptor Pharmaceutical Corp. Announces Closing of $7.5 Million Registered Direct Offering
8. MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device
9. Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema
10. China Medicine Announces Changes to Management Team
11. PDI Announces New Pharmaceutical Services Business Win With a Top 5 Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
Breaking Medicine News(10 mins):